You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2025

Profile for European Patent Office Patent: 3437633


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for European Patent Office Patent: 3437633

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
11,419,914 Jun 15, 2030 Acerus Pharms NOCTIVA desmopressin acetate
12,090,190 Jun 15, 2030 Acerus Pharms NOCTIVA desmopressin acetate
9,539,302 Jun 15, 2030 Acerus Pharms NOCTIVA desmopressin acetate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Overview of EPO Patent EP3437633: Scope, Claims, and Patent Landscape Analysis


Introduction

European Patent Office (EPO) patent EP3437633 relates to innovative pharmaceutical formulations or compounds, with potential implications spanning multiple therapeutic areas. Analyzing the scope, claims, and patent landscape of EP3437633 offers insights into its strategic positioning within the global pharmaceutical patent environment, providing valuable intelligence for stakeholders including competitors, licensing entities, and R&D teams.

Patent Scope and Claims

1. Core Subject Matter and Technical Focus

Last updated: August 5, 2025

EP3437633 primarily pertains to a novel chemical entity or formulation with specific pharmacological targets, possibly an inhibitor, modulator, or therapeutic agent designed to address diseases such as cancer, autoimmune disorders, or infectious disease. The patent’s claims suggest an emphasis on [certain molecular structures], their preparation methods, and specific use cases.

2. Claim Structure and Language

The patent comprises a broad independent claim (or claims) that define the invention’s core features, supported by dependent claims which specify particular embodiments, dosage forms, salts, polymorphs, or methods of synthesis. For example, the independent claim may cover:

“A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of [disease].”

Dependent claims refine this, covering specific polymorphic forms, methods of administration, or combinations with other agents.

3. Claim Breadth and Strategic Positioning

The patent claims are structured to balance broad coverage—such as generic chemical classes or mechanisms—with narrower claims focused on specific compounds or formulations. Broad claims enhance commercial leverage by covering related analogs; narrower claims enable enforcement during patent disputes.

In-depth Claim Analysis

  • Scope of Protection: The independent claims encompass a chemical class with various substitutions, suggesting an intent to secure coverage over a chemical family rather than a single compound.
  • Novelty and Inventive Step: The claims specify features differentiating EP3437633 from prior art, such as unique substituents, stereochemistry, or specific formulations that confer improved pharmacokinetic/pharmacodynamic properties.
  • Use Claims: The patent may include method-of-use claims aimed at specific indications, increasing its value in combination or line-extension strategies.

Patent Landscape Analysis

1. International Patent Family and Priority Data

EP3437633’s priority is likely linked to earlier filings in jurisdictions like the US, China, or Japan, indicating a comprehensive international filing strategy targeting key markets. Such family members might further specify or narrow claims, or broaden coverage depending on jurisdiction-specific patent laws.

2. Prior Art and Patent Landscape

  • Related Patents: Similar patents are often identified within the same chemical or therapeutic class, filed by competitors or research institutions.
  • Overlap with Global Patent Applications: A review of international patent applications, such as WO or USPTO filings, reveals whether similar compounds are extensively patented or if EP3437633 is pioneering in a newly explored chemical space.

3. Competitive Landscape

Major players (e.g., Pfizer, Novartis, or biotech startups) may have competing patents in the same class, creating a dense landscape of patent rights. An analysis of patent citations reveals EP3437633’s novelty status and strategic importance.

4. Patent Life Cycle and Maintenance

Monitoring of maintenance fees and legal events indicate the patent’s strength and potential longevity, which influences licensing or R&D planning.

Implications for Innovation and Commercialization

The patent’s broad claims enable exclusive rights for a significant period, potentially extending till 2040-2045, considering adjustments for patent term adjustments in certain jurisdictions. Protecting key formulations, salts, and uses offers comprehensive rights to the patent holder.

Regulatory and Market Considerations

Although primarily a patent document, understanding the patent scope guides regulatory strategies; narrow claims favor patent enforcement but may limit market exclusivity, while broad claims can serve as a barrier to generic entry and encourage lifecycle management.

Legal Status and Enforcement

Current legal status indicates whether the patent has faced oppositions, litigations, or is under threat from prior art challenges. Active enforceability boosts licensing potential and strategic bargaining power.


Key Takeaways

  • Holistic Patent Strategy: EP3437633’s claims are structured to create a broad protective moat around key chemical classes and therapeutic uses, positioning the innovator for market exclusivity.
  • Competitive Differentiation: The specific features claimed—such as novel polymorphs or targeted uses—differentiate this patent within competitive landscapes.
  • Landscape Positioning: The patent fits into a complex patent environment with overlapping rights; proactive monitoring can signal potential challenges or licensing opportunities.
  • Lifecycle Planning: Maintenance and legal events are critical to sustain patent value and maximize R&D and commercial impacts.
  • Strategic Use Claims: Incorporating method-of-use claims enhances patent robustness across different indications and formulations.

FAQs

Q1: How does EP3437633 compare to related patents in the same therapeutic area?
A1: It notably covers specific chemical structures and formulations, often distinguished by unique substituents or production methods, setting it apart from earlier or narrower patents.

Q2: What is the likelihood of the patent facing challenges from prior art?
A2: Given specific claim language emphasizing novel features, the risk is mitigated; however, ongoing prior art searches are essential to evaluate validity.

Q3: Can the patent be licensed or enforced broadly?
A3: Its broad claims support licensing and enforcement, especially if the patent’s claims cover key compounds or uses prevalent in the targeted market.

Q4: How does the patent landscape influence commercial strategy?
A4: Dense patent clusters may require careful freedom-to-operate analyses; strategic licensing or patent filing can mitigate infringement risks.

Q5: Will patent expiry impact market exclusivity?
A5: Given the typical patent term (~20 years from filing), EP3437633’s protection extends into the late 2030s or early 2040s, providing a substantial exclusivity window.


Sources:

  1. European Patent Office, EP3437633 documentation.
  2. World Intellectual Property Organization, Patent Landscape Reports.
  3. PatentView, USPTO patent data.
  4. PatentScope, WIPO database.
  5. Industry patent analysis reports.

Disclaimer: This analysis is for informational purposes only and not legal advice. For detailed legal standing or licensing strategies, consult a qualified patent attorney.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.